US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.
You may also be interested in...
Not all PTAB changes floated in advanced notice of proposed rulemaking will be pursued, and the rule may be split into two, USPTO Director Vidal testifies. Industry groups criticize the proposals.
Not all PTAB changes floated in advanced notice of proposed rulemaking will be pursued, and the rule may be split into two, USPTO Director Vidal testifies. PhRMA, BIO, AAM criticize the proposals.
At Solicitor General’s Urging, Supreme Court May Take Up Patent Eligibility Dispute Riling Biopharma
Federal Circuit’s rulings on subject matter patent eligibility have fractured the court, the US government says in advising the high court to review American Axle v. Neapco to provide clarity. BIO, former PTO director Kappos and Sen. Tillis also urge Supreme Court to hear the case.